IRCT20200904048610N1
Not yet recruiting
Phase 1
Safety and Efficacy of Bone marrow derived-mesenchymal stem cells in comparison with their exosomes in Amyotrophic Lateral Sclerosis: A randomized controlled phase 1 study
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Amyotrophic Lateral Sclerosis.
- Sponsor
- Mashhad University of Medical Sciences
- Enrollment
- 5
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Definitive diagnosis of ALS (according to laboratory findings or El Escorial criteria)
- •Duration of symptoms less than 36 months
- •Progressive muscle weakness in the lower limb, based on EMG in the lower limb bilaterally
- •Mandatory vital capacity more than 60% of the predicted normal in lying on the back
- •Age 18 and above
- •Ability to provide informed consent
- •The person can be geographically available and refer for the required visits.
- •Being accompanied by a caregiver and performing the care needed by him during the study
- •Failure to use riluzole or a fixed dose in the previous 30 days or more
- •In women of reproductive age, having a negative pregnancy test before stem cell injection
Exclusion Criteria
- •Use of aggressive breathing equipment
- •Diagnosis of other significant or unstable medical and clinical conditions that can interfere with the study.
- •The occurrence of any of the following situations: Alcohol consumption with illegal and non\-prescription drugs, Appearance of known immunodeficiency syndrome, Unstable medical conditions, Occurrence of unstable psychiatric diseases including psychosis, or major depression
- •People of reproductive age who are not interested in birth control.
- •Receiving any other investigational device or drug
- •Any condition in the lower limb that prevents the testing of muscle strength
- •Any condition that the specialist feels can cause difficulty in performing injections and follow\-ups
- •Any condition or subset of ALS that the researcher feels could interfere with the study or final interpretation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Research study aiming at investigating the potential effectiveness and safety of a treatment for chronic advanced heart failure of ischemic origin. The treatment is based on patient own stem cells that will be collected and guided to the cardiac cells lineage before being injected into the heart muscle.Chronic advanced symptomatic heart failure secondary to ischemic cardiomyopathyMedDRA version: 19.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001117-13-PLCelyad SA240
Active, not recruiting
Phase 1
Research study aiming at investigating the potential effectiveness and safety of a treatment for chronic advanced heart failure of ischemic origin. The treatment is based on patient own stem cells that will be collected and guided to the cardiac cells lineage before being injected into the heart muscle.Chronic advanced symptomatic heart failure secondary to ischemic cardiomyopathyMedDRA version: 17.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001117-13-IECardio3 BioSciences SA240
Active, not recruiting
Phase 1
Research study aiming at investigating the potential effectiveness and safety of a treatment for chronic advanced heart failure of ischemic origin. The treatment is based on patient own stem cells that will be collected and guided to the cardiac cells lineage before being injected into the heart muscle.Chronic advanced symptomatic heart failure secondary to ischemic cardiomyopathyMedDRA version: 17.1 Level: LLT Classification code 10010684 Term: Congestive heart failure System Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001117-13-HRCardio3 BioSciences SA240
Active, not recruiting
Phase 1
Research study aiming at investigating the potential effectiveness and safety of a treatment for chronic advanced heart failure of ischemic origin. The treatment is based on patient own stem cells that will be collected and guided to the cardiac cells lineage before being injected into the heart muscle.Chronic advanced symptomatic heart failure secondary to ischemic cardiomyopathyMedDRA version: 18.1Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001117-13-BGCelyad SA240
Active, not recruiting
Phase 1
Efficacy and Safety of Bone Marrow-Derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure - Congestive Heart failure cArdiopoietic Regenerative Therapy-1 (CHART-1) trialChronic advanced symptomatic heart failure secondary to ischemic cardiomyopathyMedDRA version: 17.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-001117-13-HUCardio3 BioSciences SA290